Related Experiment Video

Updated: Jan 21, 2026

Author Spotlight: Exploring the Frontier of mRNA Research with Poly A Tail Analysis Techniques
08:16

Author Spotlight: Exploring the Frontier of mRNA Research with Poly A Tail Analysis Techniques

Published on: January 12, 2024

1.4K

Current role of poly(ADP-ribose) polymerase inhibitors: which poly(ADP-ribose) polymerase inhibitor and when?

Hélène Vanacker, Clémence Romeo, Isabelle Ray-Coquard

    Current Opinion in Oncology
    |July 24, 2019
    PubMed
    Abstract

    Insights

    Poly(ADP-ribose) polymerase inhibitors (PARPi) offer a revolutionary treatment for ovarian cancer by exploiting homologous recombination deficiency (HRD) in BRCA-mutated patients, leading to synthetic lethality.

    Area of Science:

    • Oncology
    • Genetics
    • Pharmacology

    Background:

    • Ovarian cancer management has been revolutionized by poly(ADP-ribose) polymerase inhibitors (PARPi).
    • Patients with BRCA1/2 mutations exhibit distinct clinical behaviors and treatment responses.
    • BRCA gene mutations lead to homologous recombination deficiency (HRD), a critical factor in treatment efficacy.

    Purpose of the Study:

    • To review the impact of PARP inhibitors in ovarian cancer management.
    • To explore the therapeutic potential of targeting HRD in ovarian cancer.
    • To address key questions regarding PARPi efficacy, patient selection, and treatment strategies.

    Main Methods:

    • Review of recent advancements in PARP inhibitor therapy for ovarian cancer.
    • Analysis of the synthetic lethality principle in the context of HRD and PARPi.
    • Discussion of clinical questions and future research directions for PARPi use.

    Main Results:

    • PARPi exploit HRD in BRCA-mutated ovarian cancer, inducing synthetic lethality by inhibiting DNA repair.
    • HRD presents a significant therapeutic opportunity for targeted treatment with PARPi.
    • Significant questions remain regarding optimal patient populations, treatment timing, drug equivalence, and resistance strategies.

    Conclusions:

    • PARPi represent a major breakthrough in ovarian cancer treatment, particularly for patients with HRD.
    • Further research is needed to optimize PARPi use, address resistance, and define ideal combination strategies.
    • Understanding HRD is crucial for maximizing the benefits of PARPi in ovarian cancer therapy.

    More Related Videos

    Synthesis of Terpolymers at Mild Temperatures Using Dynamic Sulfur Bonds in PolyS-Divinylbenzene09:16

    Synthesis of Terpolymers at Mild Temperatures Using Dynamic Sulfur Bonds in PolyS-Divinylbenzene

    Published on: May 20, 2019

    8.2K
    Rapid Development of Cell State Identification Circuits with Poly-Transfection09:21

    Rapid Development of Cell State Identification Circuits with Poly-Transfection

    Published on: February 24, 2023

    2.0K

    Related Concept Videos

    Bacterial RNA Polymerase00:43

    Bacterial RNA Polymerase

    Unlike eukaryotes, bacteria use a single RNA Polymerase (RNAP) to transcribe all genes. The different subunits of bacterial RNAPhave distinct functions. The multisubunit structure of the bacterial RNAP helps the enzyme to maintain catalytic function, facilitate assembly, interact with DNA and RNA, and self-regulate its activity.
    In most genes, the transcription site is a single base present upstream of the coding sequence. Though RNAP is a catalytically efficient enzyme, it does not recognize...
    32.5K
    Bacterial RNA Polymerase00:43

    Bacterial RNA Polymerase

    11.6K
    Eukaryotic Transcription Inhibitors01:52

    Eukaryotic Transcription Inhibitors

    Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
    Eukaryotic transcription inhibitors usually contain two distinct domains, a...
    10.9K
    The ADP/ATP Carrier Protein01:42

    The ADP/ATP Carrier Protein

    ADP/ATP carrier or AAC protein is the most abundant carrier protein in the inner mitochondrial membrane. It transports large quantities of ADP and ATP, equivalent to the average human body weight, every day. Among other transporters, ACC protein is one of the best-studied members of the mitochondrial carrier protein family. The ADP/ATP carrier protein comprises two transmembrane helices connected to a loop and a single alpha-helix on the matrix side. It switches between two conformational...
    4.2K
    Translesion DNA Polymerases02:10

    Translesion DNA Polymerases

    Translesion (TLS) polymerases rescue stalled DNA polymerases at sites of damaged bases by replacing the replicative polymerase and installing a nucleotide across the damaged site. Doing so, TLS allows additional time for the cell to repair the damage before resuming regular DNA replication.
    TLS polymerases are found in all three domains of life - archaea, bacteria, and eukaryotes. Of the different classes of TLS polymerases, members of the Y family are fitted with specialized structures that...
    11.1K
    Eukaryotic RNA Polymerases00:58

    Eukaryotic RNA Polymerases

    RNA Polymerase (RNAP) is conserved in all animals, with bacterial, archaeal, and eukaryotic RNAPs sharing significant sequence, structural, and functional similarities. Among the three eukaryotic RNAPs, RNA Polymerase II is most similar to bacterial RNAP in terms of both structural organization and folding topologies of the enzyme subunits. However, these similarities are not reflected in their mechanism of action.
    All three eukaryotic RNAPs require specific transcription factors, of which the...
    26.8K